Weikang Pharmaceutical announced that the company recently received the “Notice of Approval of Supplementary Application for Drug Clinical Trials” for Huangjia Soft Liver granules approved and issued by the State Drug Administration. The drug is a Class 1.1 granule of traditional Chinese medicine. The indication is chronic viral hepatitis B liver fibrosis, and it has agreed to carry out phase III clinical trials on the basis of improving the clinical trial plan. It is necessary to complete phase III clinical trials and marketing license applications before it can be listed. There is uncertainty about R&D and market prospects, and it will not have a significant impact on the company's recent performance.

Weikang Pharmaceutical announced that the company recently received the “Notice of Approval of Supplementary Application for Drug Clinical Trials” for Huangjia Soft Liver granules approved and issued by the State Drug Administration. The drug is a Class 1.1 granule of traditional Chinese medicine. The indication is chronic viral hepatitis B liver fibrosis, and it has agreed to carry out phase III clinical trials on the basis of improving the clinical trial plan. It is necessary to complete phase III clinical trials and marketing license applications before it can be listed. There is uncertainty about R&D and market prospects, and it will not have a significant impact on the company's recent performance.